Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

CureVac-GSK coronavirus variant vaccine generates good immune response in rats

CoronavirusMay 13, 2021 11:07AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: German biotechnology company CureVac's vaccination against the coronavirus disease (COVID-19) is given to a volunteer at the start of a clinical test series in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach/File Photo

By Alistair Smout

LONDON (Reuters) - A second-generation COVID-19 vaccine developed by CureVac and GlaxoSmithKline (NYSE:GSK), designed to protect against coronavirus variants, produced a high level of immune response in a trial in rats, the companies said on Thursday.

CureVac in February said it would team up with GlaxoSmithKline on a COVID-19 vaccine aimed at targeting several variants with one shot.

The shot uses messenger RNA technology, similar to successful vaccines made by Pfizer-BioNTech and Moderna (NASDAQ:MRNA), and clinical trials of the shot in humans are expected to start in the third quarter of this year.

The mRNA "backbone" of the shot differs from CureVac's first COVID-19 vaccine candidate, and it is designed to work well at lower doses.

Rats immunised with the shot, called CV2CoV, showed quick, strong immune responses, the companies said, and blood serum "showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351)."

"To successfully fight the COVID-19 pandemic in the long term, we will need different vaccines and we need to be able to respond effectively to emerging variants," GSK Global Vaccines President Roger Connor said.

"We are pleased with these pre-clinical results as they show the potential of the next generation mRNA technology we are developing together with CureVac."

Although human trials are yet to start, these results mark a boost for GSK, the world's largest vaccine maker by sales.

GSK's collaboration with CureVac is a fresh attempt to play a major role in fighting the pandemic after a COVID-19 shot with Sanofi (NASDAQ:SNY) ran into delays and a collaboration with China's Clover Biopharmaceuticals was ended.

GSK, which acquired a 10% stake in CureVac last year, will also support the production of up to 100 million doses of CureVac's first-generation COVID-19 vaccine candidate.

CureVac's first generation COVID-19 vaccine is already in late-stage clinical trials.

CureVac-GSK coronavirus variant vaccine generates good immune response in rats
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email